Summary
Background: Accurate measurement of the size of breast cancers becomes more important as breast cancer therapy advances. This study reports the accuracy of magnetic resonance imaging (MRI), ultrasonography and mammography for measuring the largest breast cancer diameter in comparison to the pathology measurement.
Materials and methods: Fourteen breast cancers were examined in 13 women with MRI, ultrasonography and mammography. The age range was 31–73 (mean 56). Six of the cancers were in premenopausal women. The MRI was performed with the intravenous injection of gadolinium based contrast agent and a three dimensional fast spoiled gradient echo sequence with fat suppression. The largest cancer diameter was measured with each imaging technique and compared to the largest cancer diameter measured at pathology.
Results: At pathological examination cancers ranged from 0.6 to 6 cm (mean 2.2) in largest diameter. MRI measurements had the highest correlation coefficient (r = 0.98) and the smallest standard error (0.34). Ultrasonography measurements had a correlation coeffient of r = 0.45 and a standard error of 0.78. Mammography measurements had a correlation coefficient of r = 0.46 and a standard error of 1.04.
Conclusions: MRI was more accurate than ultrasonography and mammography in measuring the largest cancer diameters in this group of women. This was particularly evident for several larger cancers, and a postchemotherapy cancer.
This is a preview of subscription content, log in via an institution to check access.
References
Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, de Yoldi GC, Zucali R, Rilke F, Andreola S, Silvestrini R, Di Fronzo G, Valagussa P: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82: 1539–1545, 1990
Jacquillat C, Weil M, Baillet F, Borel CH, Auclerc G, de Maublanc MA, Housset M, Forget G, Thill L, Soubrane C, Khayat D: Results of neoadjuvant chemotherapy and radiation therapy in breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66: 119–129, 1990
Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR: Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46: 2578–2581, 1986
DeVita VT: Principles of chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer Principles and Practice of Oncology, 3rd ed. J.B. Lippincott, Philadelphia, 1989, pp 288–289
Heywang SH, Hilbertz T, Beck R, Bauer WM, Eiermann W, Permanetter W: Gd-DTPA enhanced MR imaging of the breast in patients with postoperative scarring and silicon implants. J Comput Assist Tomogr 14: 348–356, 1990
Heywang SH, Wolf A, Pruss E, Hilbertz T, Eiermann W, Permanetter W: MR imaging of the breast with Gd-DTPA: use and limitations. Radiology 171: 95–103, 1989
Kaiser WA, Zietler E: MR imaging of the breast: fast imaging sequences with and without Gd-DTPA: preliminary observations. Radiology 170: 681–686, 1989
Pierce WB, Harms SE, Flamig DP, Griffey RH, Evans WP, Hagans JE: Three-dimensional gadolinium-enhanced MR imaging of the breast: Pulse sequence with fat suppression and magnetization transfer contrast: work in progress. Radiology 181: 757–763, 1991
Dao TH, Rahmouni A, Campana F, Laurent M, Asselain B, Fourquet A: Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinum-enhanced MR imaging. Radiology 187: 751–753, 1993
Harms SE, Flamig DP, Hesley KL, Meiches MD, Jensen RA, Evans WP, Savino DA, Wells RV: MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 187: 493–501, 1993
Gilles R, Guenebretière J-M, Shapeero LG, Lesnik A, Contesso G, Sarrazin D, Masselot J, Vanel D: Assessment of breast cancer recurrence with contrast-enhanced subtraction MRI: preliminary results in 26 patients. Radiology 188: 473–474, 1993
Lewis-Jones H, Whitehouse G, Leinster S: The role of magnetic resonance imaging in the assessment of local recurrent breast carcinoma. Clin Rad 42: 197–204, 1991
Zar JH: Biostatistical Analysis. Prentice-Hall, Inc., NJ, 1974
Merchant TE, Obertop H, deGraaf PW: Advantages of magnetic resonance imaging in breast surgery treatment planning. Breast Cancer Res Treat 25: 257–265, 1993
Gribbestad IS, Nilsen G, Føsne H, Fougner R, Haugen OA, Petersen SB, Rinck PA, Kvinnsland S: Contrast-enhanced magnetic resonance imaging of the breast. Acta Oncol 31: 833–842, 1992
Fornage BD, Toubas O, Morel M: Clinical, mammographic, and sonographic determination of preoperative breast cancer size. Cancer 60: 765–771, 1987
Kedar RP, Cosgrove DO, Smith IE, Mansi JL, Bamber JC: Breast carcinoma: measurement of tumor response to primary medical therapy with color Doppler flow imaging. Radiology 190: 825–830, 1994
Moertel CG, Hanley JA: The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 38: 388–394, 1976
Jernigan TL, Press GA, Hesselink JR: Methods for measuring brain morphologic features on magnetic resonance images: validation and normal aging. Arch Neurol 47: 27–32, 1990
Rusinek H, Chandra R: Brain tissue volume measurements from magnetic resonance imaging. Invest Radiol 28: 890–895, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Davis, P.L., Staiger, M.J., Harris, K.B. et al. Breast cancer measurements with magnetic resonance imaging, ultrasonography, and mammography. Breast Cancer Res Tr 37, 1–9 (1996). https://doi.org/10.1007/BF01806626
Issue Date:
DOI: https://doi.org/10.1007/BF01806626